Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment
- 726 Downloads
Treatment of parapneumonic empyema (PE) consists of intravenous antibiotics and, in case of large effusions and persisting fever, pleural chest drain (±intrapleural fibrinolytics) or video-assisted surgical intervention. We standardized the treatment for PE in our tertiary care center choosing a first-step nonsurgical approach. The aim was to evaluate the need for surgery and to collect data on disease course, outcome, and microbiology. For all children treated for PE between 2006 and 2013, data were prospectively collected concerning treatment, length of stay, duration of fever, complications, and causative agent. Of 132 children treated for PE, 20 % needed surgical intervention. Analyzed per year, the need for surgery decreased from almost 40 % in 2007 to 0 % in 2010 again increasing to 40 % although this did not reach statistical significance (p = 0.115). Median duration of “in-hospital fever” was 5 days (IQR, 3–8). The duration of fever correlated with pleural LDH (r = 0.324; p = 0.002) and pleural glucose (r = −0.248; p = 0.021) and was inversely correlated with pleural pH (r = −0.249; p = 0.046). Based on pleural PCR data, 85 % of PE were caused by Streptococcus pneumoniae (40 % serotype 1). Conclusion: After introduction of a standardized primary medical approach (chest drain ± fibrinolysis) for PE in our institution, the need for surgical rescue interventions overall remained at 20 %, which is higher than in some other reports. Difference in microbiology or disease severity could not be proven.
KeywordsEmpyema Children Treatment Etiology
List of abbreviations
Length of stay
Video-assisted thoracoscopic surgery
Conflict of interest
The authors declare no conflict of interest. This is a nonsponsored study.
- 5.Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO, Kaplan S, Carroll KC, Daly JA, Christenson JC, Samore MH (2002) An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis 34:434–440PubMedCrossRefGoogle Scholar
- 9.Galmes J, Li Y, Rajoharison A, Ren L, Dollet S, Richard N, Vernet G, Javouhey E, Wang J, Telles JN, Paranhos-Baccala G (2012) Potential implication of new torque teno mini viruses in parapneumonic empyema in children. Eur Respir J 42:470–479Google Scholar
- 11.Goossens MC, Catry B, Verhaegen J (2012) Antimicrobial resistance to benzylpenicillin in invasive pneumococcal disease in Belgium, 2003–2010: the effect of altering clinical breakpoints. Epidemiol Infect 141:490–495Google Scholar
- 28.Strachan RE, Cornelius A, Gilbert GL, Gulliver T, Martin A, McDonald T, Nixon G, Roseby R, Ranganathan S, Selvadurai H, Smith G, Soto-Martinez M, Suresh S, Teoh L, Thapa K, Wainwright CE, Jaffe A (2012) Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children. Respirology 17:114–119PubMedCrossRefGoogle Scholar